tiprankstipranks
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
US Market
TARS
Tarsus Pharmaceuticals
RESEARCH TOOLSreports

Tarsus Pharmaceuticals (TARS) Stock Forecast & Price Target

266 Followers
See the Price Targets and Ratings of:

TARS Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Tarsus
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TARS Stock 12 Month Forecast

Average Price Target

$89.67
▲(27.88% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Tarsus Pharmaceuticals in the last 3 months. The average price target is $89.67 with a high forecast of $105.00 and a low forecast of $68.00. The average price target represents a 27.88% change from the last price of $70.12.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","55":"$55","72":"$72","89":"$89","106":"$106"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$105.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":89.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$89.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$68.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,55,72,89,106],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.22,72.89538461538461,75.57076923076923,78.24615384615385,80.92153846153846,83.59692307692308,86.27230769230769,88.94769230769231,91.62307692307692,94.29846153846154,96.97384615384615,99.64923076923077,102.32461538461538,{"y":105,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.22,71.71615384615384,73.21230769230769,74.70846153846153,76.20461538461538,77.70076923076923,79.19692307692307,80.69307692307692,82.18923076923078,83.68538461538462,85.18153846153847,86.67769230769231,88.17384615384616,{"y":89.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.22,70.04923076923077,69.87846153846154,69.70769230769231,69.53692307692307,69.36615384615385,69.19538461538461,69.02461538461539,68.85384615384615,68.68307692307692,68.51230769230769,68.34153846153846,68.17076923076922,{"y":68,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.99,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.81,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.81,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.97,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.93,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 60, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.43,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 64, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.22,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 59, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$105.00Average Price Target$89.67Lowest Price Target$68.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on TARS
Eddie Hickman
Guggenheim
Guggenheim
$90
Buy
28.35%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (Other OTC: PRNAF), Tarsus Pharmaceuticals (NASDAQ: TARS) and enGene Holdings (NASDAQ: ENGN)
LifeSci Capital Analyst forecast on TARS
Francois Brisebois
LifeSci Capital
LifeSci Capital
$95
Buy
35.48%
Upside
Reiterated
04/01/26
Tarsus Pharmaceuticals (TARS) Receives a Buy from LifeSci Capital
Mizuho Securities Analyst forecast on TARS
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$70.15→$101
Buy
44.04%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (NASDAQ: TARS) and Forte Biosciences (NASDAQ: FBRX)
William Blair Analyst forecast on TARS
Lachlan Hanbury Brown
William Blair
William Blair
$70
Buy
-0.17%
Downside
Assigned
03/31/26
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
Barclays Analyst forecast on TARS
Jenna Davidner
Barclays
Barclays
$100
Buy
42.61%
Upside
Reiterated
03/27/26
Barclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)
Oppenheimer Analyst forecast on TARS
Andreas Argyrides
Oppenheimer
Oppenheimer
$95→$105
Buy
49.74%
Upside
Reiterated
02/25/26
Analysts Are Bullish on Top Healthcare Stocks: Tarsus Pharmaceuticals (TARS), Option Care Health (OPCH)
Bank of America Securities Analyst forecast on TARS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$88→$90
Buy
28.35%
Upside
Assigned
02/24/26
Tarsus: Strong Xdemvy Launch, Upgraded Long‑Term Outlook, and Underappreciated Earnings Power Support Buy Rating
H.C. Wainwright Analyst forecast on TARS
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$88
Buy
25.50%
Upside
Reiterated
02/24/26
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
Goldman Sachs Analyst forecast on TARS
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$68
Hold
-3.02%
Downside
Reiterated
02/11/26
Balanced Risk-Reward for Tarsus as Xdemvy Momentum Meets TP-04 Development Uncertainty, Supporting a Hold Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on TARS
Eddie Hickman
Guggenheim
Guggenheim
$90
Buy
28.35%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Alterity Therapeutics (Other OTC: PRNAF), Tarsus Pharmaceuticals (NASDAQ: TARS) and enGene Holdings (NASDAQ: ENGN)
LifeSci Capital Analyst forecast on TARS
Francois Brisebois
LifeSci Capital
LifeSci Capital
$95
Buy
35.48%
Upside
Reiterated
04/01/26
Tarsus Pharmaceuticals (TARS) Receives a Buy from LifeSci Capital
Mizuho Securities Analyst forecast on TARS
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$70.15→$101
Buy
44.04%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (NASDAQ: TARS) and Forte Biosciences (NASDAQ: FBRX)
William Blair Analyst forecast on TARS
Lachlan Hanbury Brown
William Blair
William Blair
$70
Buy
-0.17%
Downside
Assigned
03/31/26
Buy Rating Backed by Blockbuster Xdemvy Launch and TP-05 Lyme Prevention Opportunity
Barclays Analyst forecast on TARS
Jenna Davidner
Barclays
Barclays
$100
Buy
42.61%
Upside
Reiterated
03/27/26
Barclays Reaffirms Their Buy Rating on Tarsus Pharmaceuticals (TARS)
Oppenheimer Analyst forecast on TARS
Andreas Argyrides
Oppenheimer
Oppenheimer
$95→$105
Buy
49.74%
Upside
Reiterated
02/25/26
Analysts Are Bullish on Top Healthcare Stocks: Tarsus Pharmaceuticals (TARS), Option Care Health (OPCH)
Bank of America Securities Analyst forecast on TARS
Jason Gerberry
Bank of America Securities
Bank of America Securities
$88→$90
Buy
28.35%
Upside
Assigned
02/24/26
Tarsus: Strong Xdemvy Launch, Upgraded Long‑Term Outlook, and Underappreciated Earnings Power Support Buy Rating
H.C. Wainwright Analyst forecast on TARS
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
$88
Buy
25.50%
Upside
Reiterated
02/24/26
Sustained Growth Outlook for Tarsus Driven by XDEMVY’s Rapid Ramp and Expanding Lotilaner Pipeline
Goldman Sachs Analyst forecast on TARS
Andrea Newkirk
Goldman Sachs
Goldman Sachs
$68
Hold
-3.02%
Downside
Reiterated
02/11/26
Balanced Risk-Reward for Tarsus as Xdemvy Momentum Meets TP-04 Development Uncertainty, Supporting a Hold Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tarsus Pharmaceuticals

3 Months
xxx
Success Rate
11/18 ratings generated profit
61%
Average Return
+23.13%
reiterated a xxx
 rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 61.11% of your transactions generating a profit, with an average return of +23.13% per trade.
1 Year
Francois BriseboisLifeSci Capital
Success Rate
16/18 ratings generated profit
89%
Average Return
+69.57%
reiterated a buy rating 6 days ago
Copying Francois Brisebois's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +69.57% per trade.
2 Years
xxx
Success Rate
17/18 ratings generated profit
94%
Average Return
+141.40%
reiterated a xxx
 rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 94.44% of your transactions generating a profit, with an average return of +141.40% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TARS Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
1
4
4
Buy
12
11
31
36
36
Hold
11
15
60
64
59
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
26
92
104
99
In the current month, TARS has received 40 Buy Ratings, 59 Hold Ratings, and 0 Sell Ratings. TARS average Analyst price target in the past 3 months is 89.67.
Each month's total comprises the sum of three months' worth of ratings.

TARS Financial Forecast

TARS Earnings Forecast

Next quarter’s earnings estimate for TARS is -$0.30 with a range of -$0.52 to -$0.02. The previous quarter’s EPS was -$0.20. TARS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TARS has Performed in-line its overall industry.
Next quarter’s earnings estimate for TARS is -$0.30 with a range of -$0.52 to -$0.02. The previous quarter’s EPS was -$0.20. TARS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year TARS has Performed in-line its overall industry.

TARS Sales Forecast

Next quarter’s sales forecast for TARS is $153.12M with a range of $145.00M to $165.13M. The previous quarter’s sales results were $151.67M. TARS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TARS has Performed in-line its overall industry.
Next quarter’s sales forecast for TARS is $153.12M with a range of $145.00M to $165.13M. The previous quarter’s sales results were $151.67M. TARS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year TARS has Performed in-line its overall industry.

TARS Stock Forecast FAQ

What is TARS’s average 12-month price target, according to analysts?
Based on analyst ratings, Tarsus Pharmaceuticals’s 12-month average price target is 89.67.
    What is TARS’s upside potential, based on the analysts’ average price target?
    Tarsus Pharmaceuticals has 27.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TARS a Buy, Sell or Hold?
          Tarsus Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Tarsus Pharmaceuticals’s price target?
            The average price target for Tarsus Pharmaceuticals is 89.67. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $105.00 ,the lowest forecast is $68.00. The average price target represents 27.88% Increase from the current price of $70.12.
              What do analysts say about Tarsus Pharmaceuticals?
              Tarsus Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of TARS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.